Index
RUT
Market Cap
688.54M
Enterprise Value
548.36M
Income
-198.96M
Sales
0.00M
Book/sh
0.75
Cash/sh
1.12
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
96
IPO
Jul 24, 2020
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
4.80
P/C
3.23
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
5.79
Current Ratio
5.79
Debt/Eq
0.51
LT Debt/Eq
0.49
Option/Short
Yes / Yes
EPS (ttm)
-1.03
EPS next Y
-0.99
EPS next Q
-0.26
EPS this Y
24.06%
EPS next Y
3.09%
EPS next 5Y
52.84%
EPS past 3/5Y
19.69% 20.17%
Sales past 3/5Y
- -
EPS Y/Y TTM
26.90%
Sales Y/Y TTM
-
EPS Q/Q
32.04%
Sales Q/Q
-
Insider Own
13.00%
Insider Trans
2.65%
Inst Own
95.50%
Inst Trans
11.64%
ROA
-82.98%
ROE
-130.80%
ROIC
-93.52%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
-8.57%
SMA50
-8.88%
SMA200
-28.65%
Trades
Shs Outstand
190.09M
Shs Float
165.96M
52W High
7.18 -49.73%
52W Low
2.99 20.72%
Volatility
7.80% 6.96%
ATR (14)
0.27
RSI (14)
40.43
Beta
1.47
Rel Volume
0.66
Avg Volume
3.29M
Volume
1,901,195
Perf Week
-13.86%
Perf Month
-5.76%
Perf Quarter
-30.32%
Perf Half Y
-28.38%
Perf YTD
-28.10%
Perf Year
12.79%
Perf 3Y
38.82%
Perf 5Y
-74.67%
Perf 10Y
-
Prev Close
3.47
Price
3.61
Change %
4.02%
Analysts 12 incl. previous ratings
Rating Distribution 10 Buy · 2 Hold · 0 Sell
Date Action Analyst Rating Change Price Target Change Implied Upside Aug 13, 2026 Upgrade C Citizens
Mkt Underperform → Mkt Perform Jul 21, 2026 Initiated C Citizens
Mkt Underperform $3 -16.9% May 12, 2026 Initiated G Goldman
Neutral $7 +93.9% Dec 23, 2025 Initiated C Chardan Capital Markets
Buy $16 +343.3% Mar 01, 2024 Upgrade J JP Morgan
Neutral → Overweight $11 +204.8% Dec 21, 2023 Upgrade B BofA Securities
Neutral → Buy $4 → $6 +66.2% Oct 30, 2023 Initiated W Wells Fargo
Overweight $11 +204.8% May 26, 2023 Downgrade B BofA Securities
Buy → Neutral $8 → $3 -16.9% May 25, 2023 Downgrade J JP Morgan
Overweight → Neutral $19 → $9 +149.3% Sep 16, 2022 Initiated J Jefferies
Buy $12 +232.5% Sep 09, 2022 Initiated B BTIG Research
Buy $15 +315.6% Nov 30, 2021 Initiated H H.C. Wainwright
Buy $40 +1,008.2% Sep 23, 2021 Initiated C Cantor Fitzgerald
Overweight $40 +1,008.2% Jan 26, 2021 Initiated N Needham
Buy $37 +925.1% Aug 18, 2020 Initiated J JP Morgan
Overweight $33 +814.3% Aug 18, 2020 Initiated C Cowen
Outperform Aug 18, 2020 Initiated B BofA Securities
Buy $33 +814.3%
Show Previous Ratings
Nov-17-26 04:01PM
Nov-11-26 11:24AM
Nov-09-26 04:01PM
Oct-28-26 08:00AM
Oct-16-26 05:34PM
(GlobeNewswire)
-5.28%
+17.60%
08:00AM
Loading…
Sep-24-26 08:00AM
Sep-16-26 04:05PM
Sep-02-26 08:00AM
Aug-17-26 04:05PM
Aug-12-26 07:33AM
06:05AM
06:00AM
Aug-10-26 04:05PM
Aug-06-26 08:00AM
Jul-30-26 04:01PM
(GlobeNewswire)
+8.44%
-3.32%
04:05PM
Loading…
Jul-16-26 04:05PM
Jul-14-26 04:05PM
Jun-16-26 04:05PM
May-27-26 08:00AM
May-18-26 04:05PM
May-07-26 04:01PM
(GlobeNewswire)
-3.16%
+3.08%
May-06-26 08:00AM
Apr-08-26 04:05PM
Apr-01-26 08:00PM
Mar-30-26 04:01PM
Mar-16-26 04:05PM
Mar-04-26 05:48AM
Feb-24-26 08:00AM
Feb-17-26 08:00AM
Jan-16-26 05:05PM
05:10PM
Loading…
Jan-14-26 05:10PM
(MarketBeat)
+7.92%
-7.78%
Jan-12-26 07:00AM
Jan-08-26 08:00AM
Jan-07-26 04:05PM
Dec-23-25 08:13AM
Dec-18-25 01:14AM
Dec-16-25 07:31PM
Nov-29-25 01:26AM
Nov-14-25 04:01PM
Nov-12-25 10:55PM
(GlobeNewswire)
-4.38%
-5.63%
04:12PM
Nov-10-25 04:05PM
Sep-30-25 11:41AM
Aug-27-25 08:00AM
Aug-18-25 04:05PM
(GlobeNewswire)
-3.69%
-6.81%
Aug-14-25 04:05PM
Aug-11-25 07:29AM
(Pharmaceutical Business Review)
Aug-07-25 04:30PM
Jul-24-25 07:00AM
Jul-22-25 06:16AM
Jun-18-25 04:05PM
May-29-25 04:05PM
(GlobeNewswire)
+7.39%
-6.42%
May-19-25 04:05PM
04:05PM
May-16-25 04:05PM
May-12-25 08:00AM
May-09-25 05:00PM
05:00PM
May-07-25 08:00AM
Apr-16-25 04:05PM
Apr-15-25 07:12AM
Apr-10-25 09:24AM
Apr-09-25 03:20PM
Apr-08-25 04:05PM
04:05PM
Apr-03-25 06:18PM
(GlobeNewswire)
-6.63%
-7.65%
06:18PM
Mar-17-25 04:05PM
(GlobeNewswire)
+5.77%
-9.09%
Mar-16-25 06:05AM
Mar-03-25 08:00AM
Feb-26-25 04:05PM
Feb-18-25 08:00AM
Feb-13-25 08:30AM
Jan-13-25 08:00AM
Jan-10-25 08:00AM
Jan-07-25 08:00AM
Dec-16-24 04:05PM
(GlobeNewswire)
+13.96%
-3.56%
07:30AM
Dec-05-24 08:00AM
Nov-19-24 03:00AM
Nov-15-24 04:59PM
(GlobeNewswire)
-3.32%
-10.78%
Nov-14-24 08:00AM
Nov-13-24 04:05PM
Oct-21-24 08:00PM
Oct-16-24 08:00AM
Oct-15-24 08:00AM
Sep-16-24 08:00AM
Sep-09-24 08:00AM
Sep-03-24 08:00AM
Aug-29-24 08:00AM
Aug-16-24 04:05PM
Aug-12-24 08:00AM
Aug-05-24 08:00AM
Jul-16-24 04:05PM
Jul-11-24 06:09PM
(GlobeNewswire)
+8.53%
+11.15%
Jun-29-24 08:48PM
Jun-28-24 09:40AM
Jun-27-24 09:55AM
Jun-25-24 05:00PM
05:00PM
Show Previous News
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Love Douglas PRESIDENT AND CEO Sep 24 '26 Buy 3.83 26,065 99,829 390,476 Sep 25 04:15 PM WIGGANS THOMAS G Former Director Aug 13 '26 Proposed Sale 5.30 2,000 10,596 Aug 13 03:34 PM WIGGANS THOMAS G Former Director Jul 15 '26 Proposed Sale 6.32 2,000 12,630 Jul 15 04:19 PM WIGGANS THOMAS G Former Director Jul 14 '26 Proposed Sale 5.61 1,000 5,605 Jul 14 01:56 PM Yednock Ted EVP & CHIEF INNOVATION OFFICER Jun 11 '26 Option Exercise 1.85 30,646 56,698 184,807 Jun 15 04:15 PM Satter Muneer A Director May 28 '26 Buy 5.41 613,497 3,319,019 10,342,134 May 29 05:21 PM Carson William H. Director May 11 '26 Buy 5.78 8,000 46,240 78,405 May 13 04:30 PM Carson William H. Director Apr 10 '26 Buy 6.20 8,000 49,600 70,405 Apr 14 04:16 PM Carson William H. Director Mar 10 '26 Buy 5.67 8,000 45,360 62,405 Mar 12 04:31 PM Dananberg Jamie CHIEF MEDICAL OFFICER Mar 02 '26 Sale 5.43 5,820 31,603 123,582 Mar 04 04:30 PM Overdorf Michael EVP & CHIEF BUSINESS OFFICER Mar 02 '26 Sale 5.42 4,339 23,517 182,625 Mar 04 04:30 PM Yednock Ted EVP & CHIEF INNOVATION OFFICER Mar 02 '26 Sale 5.42 5,566 30,168 154,161 Mar 04 04:30 PM ARTIS DEAN RICHARD EVP & CHIEF SCIENTIFIC OFFICER Mar 02 '26 Sale 5.43 5,894 32,004 180,093 Mar 04 04:30 PM Lew Jennifer EVP & CHIEF FINANCIAL OFFICER Mar 02 '26 Sale 5.42 5,565 30,162 170,700 Mar 04 04:30 PM Yednock Ted Officer Mar 02 '26 Proposed Sale 5.42 5,566 30,181 Mar 02 05:05 PM ARTIS DEAN RICHARD Officer Mar 02 '26 Proposed Sale 5.43 5,894 31,980 Mar 02 04:41 PM Overdorf Michael Officer Mar 02 '26 Proposed Sale 5.42 4,339 23,530 Mar 02 04:16 PM Dananberg Jamie Officer Mar 02 '26 Proposed Sale 5.43 5,820 31,579 Mar 02 04:05 PM Lew Jennifer Officer Mar 02 '26 Proposed Sale 5.42 5,565 30,178 Mar 02 04:02 PM Dananberg Jamie CHIEF MEDICAL OFFICER Feb 18 '26 Sale 5.10 5,290 26,979 73,152 Feb 20 04:30 PM Lew Jennifer EVP & CHIEF FINANCIAL OFFICER Feb 18 '26 Sale 5.11 7,851 40,119 113,765 Feb 20 04:30 PM ARTIS DEAN RICHARD EVP & CHIEF SCIENTIFIC OFFICER Feb 18 '26 Sale 5.10 5,290 26,979 123,487 Feb 20 04:30 PM Yednock Ted EVP & CHIEF INNOVATION OFFICER Feb 18 '26 Sale 5.11 7,857 40,149 97,227 Feb 20 04:30 PM Overdorf Michael EVP & CHIEF BUSINESS OFFICER Feb 18 '26 Sale 5.10 6,225 31,747 124,464 Feb 20 04:30 PM Lew Jennifer Officer Feb 18 '26 Proposed Sale 5.11 7,851 40,119 Feb 18 03:39 PM ARTIS DEAN RICHARD Officer Feb 18 '26 Proposed Sale 5.10 5,290 26,990 Feb 18 03:38 PM Yednock Ted Officer Feb 18 '26 Proposed Sale 5.11 7,857 40,122 Feb 18 03:29 PM Overdorf Michael Officer Feb 18 '26 Proposed Sale 5.10 6,225 31,764 Feb 18 03:20 PM Dananberg Jamie Officer Feb 18 '26 Proposed Sale 5.10 5,290 26,990 Feb 18 03:11 PM Carson William H. Director Dec 30 '25 Buy 5.02 4,115 20,657 54,405 Jan 02 04:30 PM Choi Jung Director Dec 01 '25 Buy 4.19 33,000 138,270 33,000 Dec 03 04:30 PM Carson William H. Director Dec 01 '25 Buy 4.47 4,115 18,394 50,290 Dec 03 04:30 PM Satter Muneer A Director Nov 21 '25 Buy 4.28 422,613 1,808,784 9,728,637 Nov 21 09:52 PM Satter Muneer A Director Nov 20 '25 Buy 4.48 400,000 1,792,000 9,306,024 Nov 21 09:52 PM Satter Muneer A Director Nov 19 '25 Buy 3.94 500,000 1,970,000 8,906,024 Nov 19 09:00 PM
Annexon, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain. It offers drugs that control or target huntington's and alzheimer's disease, multiple sclerosis, glaucoma, parkinson's disease, and spinal muscular atrophy. The company was founded by Ben Barres and Arnon Rosenthal on March 3, 2011 and is headquartered in Brisbane, CA.
J.D. Mr. Douglas E. Love Esq.
Executive VP Ms. Jennifer Lew CPA
Executive VP Dr. Ted Yednock Ph.D.
Chief Scientific Officer & Executive VP Dr. Dean R. Artis Ph.D.
Chief Human Resources Officer Ms. Linda A. Fitzpatrick